Skip to main content
. 2012 Sep;4(5):247–254. doi: 10.1177/1758834012455838

Figure 1.

Figure 1.

Phase III study comparing single-agent therapy (vinorelbine 30 mg/m2 days 1 and 8 or gemcitabine 1150 mg/m2 days 1 and 8 every 3 weeks according to the initial choice of each center) with the doublet carboplatin [area under the curve 6 every 4 weeks] plus paclitaxel (90 mg/m2 days 1, 8 and 15) [Quoix et al. 2011]. CI, confidence interval; HR, hazard ratio; OS, overall survival.